HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors.
The funds will be used to accelerate commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, which received clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025. The company also plans to further develop its extended-wear patch and heart attack detection technologies, expand its AI capabilities, and for general corporate purposes.
HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
The company holds over 20 issued patents related to its technology. For more details on the offering, visit https://ibn.fm/9iNYY. Updates and news about BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
This financing marks a significant step for HeartBeam as it moves toward broader commercial deployment of its cardiac monitoring solutions, potentially expanding access to advanced ECG diagnostics for patients outside traditional clinical settings.
